Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer

 Abstract

A retrospective analysis of CALGB trial 9344 suggested paclitaxel administration following cyclophosphamide and doxorubicin adjuvant chemotherapy is most beneficial for patients with ER? negative (ER?-) breast cancer. Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ER? and the effectiveness of adjuvant paclitaxel reflects the observation that ER? positive (ER?+) breast cancers proliferate more slowly than ER?- breast cancers. Three in vitro models (MCF-7, T47D and ZR-75) were examined to compare growth rates and paclitaxel-induced apoptosis in ER?+ and ER?- clones of the same, originally ER?+ cell line. For the T47D and ZR-75 cell lines, loss of ER? was associated with a decrease in doubling time and an increase in paclitaxel sensitivity. However, when cell culture conditions were altered to achieve equivalent cell proliferation rates, no difference in paclitaxel sensitivity was observed. Similarly, an ER?- clone of MCF-7 cells that did not exhibit an enhanced growth rate compared to its ER?+ counterpart also did not show increased paclitaxel sensitivity. The combined apoptotic effects of tamoxifen and paclitaxel on MCF-7 cells were not synergistic or even clearly additive. In these in vitro models, the effectiveness of paclitaxel correlated more closely with growth rate than ER? expression. These data suggest that measurements of tumor proliferation may provide more accurate predictive markers for the benefits of adjuvant paclitaxel than ER? analysis.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
460 - 467
doi
10.4161/cbt.3.5.810
Type
Research Paper
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer